MDxHealth US laboratory facility wins CMS CLIA certification
The Centers for Medicare and Medicaid Services (CMS) has granted Clinical Laboratory Improvements Amendments (CLIA) certification to MDxHealth's 13,448 ft² clinical laboratory facility in Irvine, California, US.
The company will market its proprietary epigenetic diagnostic service products for a number of cancer indications, through its CLIA -certified laboratory.
MDxHealth's laboratory has also passed inspection by the California Department of Health, and is now fully licensed and operational.
MDxHealth CEO Jan Groen said the company is now well-positioned to launch its patented epigenetic tests which will aid physicians in the diagnosis and personalized treatment of their patients.
The company expects to introduce its Prostate ConfirmMDx assay, in the first half of 2012.
Related Insight
Suppliers Directory
Diagnostics In Vitro Diagnostics Diagnostic Imaging Endoscopy Devices
Patient Care Patient Monitoring Surgical & Supplies Wound Care Management
Technology Automation Healthcare IT Packaging
Contract Services
Certification
Certification Intelligence
GlobalData’s new report, “External Defibrillators - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2016” provides key data, information and analysis on the global external defibrillators market. The report provides market landscape, competitive landscape and market trends information the external defibrillators market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.